USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: AURITEC PHARMACEUTICALS, INC.
Address: 1512 11th Street
SANTA MONICA, CA
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,841,351.00 11
SBIR Phase II $8,061,358.00 6
STTR Phase I $211,862.00 1

Award List:

Sustained Release Olanzapine

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this research is to minimize morbidity associated with psychotic disorders by developing injectable long-acting formulations of olanzapine (Zyprexa/R), currently a leading atypical antipsychotic agent FDA approved for the treatment of… More

Prevention of HIV Transmission in Breast Feeding Populations

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $83,975.00
Abstract:
DESCRIPTION (provided by applicant): The broad long term goal of this project is to prevent mother to child transmission of HIV through breast feeding in resource poor countries. In the developing world, perinatal transmission is greatly reduced through relatively simple expedients such as dosing… More

Intra-articular sustained release steroid injections

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The broad long-term goal of this research is to reduce morbidity due to arthritis by developing injectable long term intra-articular drug delivery systems. Intra-articular steroids have been a mainstay of treatment for arthritis for more than 50 years. For many… More

Continuous Dopaminergic Stimulation: Parkinson's Disease

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The broad long term goal of this project is to develop sustained release subcutaneous drug delivery systems in order to achieve continuous dopaminergic stimulation in the treatment of Parkinson's Disease (PD). Pulsatile dopaminergic pharmacokinetics contribute… More

Sustained release depot pre-exposure prophylaxis in breast feeding populations

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $775,307.00
Abstract:
DESCRIPTION (provided by applicant): The broad long term goal of this project is to prevent mother to child transmission of HIV through breast feeding in resource poor countries. In the developing world, perinatal transmission is greatly reduced through relatively simple expedients such as dosing… More

Sustained Release Intravitreal Corticosteroid Injections

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $99,368.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this research is to reduce or eliminate blindness due to diseases of the back of the eye by developing sustained release intravitreal injectable formulations for anti-inflammatory drugs. In previous work, supported in part through SBIR Phase… More

Sustained Release Inner Ear Delivery of Corticosteroid

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: William H. Slattery
Award Amount: $99,550.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this research is to reduce or eliminate deafness due to certain diseases of the inner ear by developing sustained release formulations for anti-inflammatory drugs which can be implanted directly in to the inner ear. The initial project will… More

Sustained release calcineurin inhibitors for the prevention of graft rejection

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $99,120.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this research is to reduce toxicity and graft rejection due to dosing problems with the calcineurin inhibitors by developing sustained release subcutaneous injectable formulations for the drugs tac rolimus and cyclosporine. Substantial… More

Sustained Release Apomrophine for Parkinson's Disease

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $696,344.00
Abstract:
DESCRIPTION (provided by applicant): The broad long term goal of this work is to develop sustained release subcutaneous drug delivery systems in order to achieve a more continuous dopaminergic stimulation in the treatment of Parkinson's Disease (PD). The i mmediate goal of this project is to develop… More

Depot calcineurin inhibitors to prevent graft rejection

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $1,330,823.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this research is to reduce toxicity and graft rejection due to dosing problems with the calcineurin inhibitors by developing a sustained release subcutaneous injectable formulation of a calcineurin inhibitor. Substantial inter-and… More

Sustained release acyclovir for prophylaxis of genital herpes

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $223,952.00
Abstract:
DESCRIPTION (provided by applicant): The broad long term goal of this project is to empower women to protect themselves from HSV and HIV infection through the development of an HSV microbicide based on sustained release drug delivery. Each day 15,000 peopl e are infected with HIV- a growing majority… More

Sustained Release Depot Olanzapine

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Thomas J. Smith
Award Amount: $1,073,894.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this research is to minimize morbidity due to non-adherence to outpatient antipsychotic-antimanic therapy with olanzapine. Olanzapine is currently a mainstay of treatment for psychotic disorders an d mania. Its elimination half-life of (ca.… More

Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Thomas J. Smith – 626-372-0386
Award Amount: $2,993,089.00
Abstract:
DESCRIPTION (provided by applicant): Large efforts are currently underway funded by the NIH, the Gates foundation, and the WHO, to reduce the spread of HIV transmission by developing an effective microbicide. The CAPRISA trial with tenofovir gel is the first demonstration of prophylaxis against HIV… More

Intravaginal ring delivery of tenofovir and emtricitabine

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith – 626-372-0386
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this project is to prevent HIV transmission. Using the drug delivery platform we developed for the ganciclovir intraocular implant, the Vitrasert(R), we propose to develop an intra-vaginal ring microbicide formulation releasing the… More

Sustained Release intravitreal VEGFR inhibition to prevent blindness

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith – 626-372-0386
Award Amount: $296,405.00
Abstract:
DESCRIPTION (provided by applicant): The broad long term goal of this project is to develop an improved treatment for neovascular age-related macular degeneration and for diabetic retinopathy: the two leading causes of blindness in the United States. The specific aims of this proposal Phase 1… More

An intravaginal ring for real-time evaluation of adherence to topical vagina

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: OAK CREST INSTITUTE OF SCIENCE
Principal Investigator: John A. Moss – 626-817-0883
Award Amount: $211,862.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The broad long-term of this project is to develop methods for evaluation of adherence to intravaginal microbicide therapy for the prevention of HIV transmission. Correct determination of adherence to preventative therapies in clinical trials is essential to… More

A Flow Through Cell Counting Assay

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas J. Smith – 626-372-0386
Award Amount: $338,981.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this project is to prevent HIV transmission. Using the drug delivery platform we developed for the ganciclovir intraocular implant, Vitrasert(R), we propose to develop an intravaginal ring microbicide formulation releasing the antiretroviral… More

Depot intra-articular fluticasone for the treatment of arthritis

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Thomas J. Smith – 626-372-0386
Award Amount: $1,191,901.00
Abstract:
DESCRIPTION (provided by applicant): The broad long-term goal of this research is to reduce morbidity due to arthritis by developing long-lasting injectable intra-articular drug delivery systems. Intra-articular steroids have been a mainstay of treatment for arthritis for more than 50 years.… More